Coherus Oncology CHRS
NASDAQ CHRS
$0.75 +0.00 (+0.56%)
As of: Nov 6, 2026 · 9:54 AM EST

Coherus Oncology (CHRS) Short term Debt (2021 - 2024)

Updated

Coherus Oncology's Short term Debt was $175 million in Q1 2024.

Analysis

Coherus Oncology (CHRS) Short term Debt (2021 - 2024) Analysis & Trends

  • The Q1 2024 figure marks the lowest quarterly Short term Debt since Q3 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,221.54 Bn 1,195.15 Bn 20.46 Bn
2 Johnson & Johnson 650.21 Bn 570.07 Bn 17.30 Bn
3 AbbVie 508.24 Bn 476.24 Bn 13.12 Bn
4 Merck 360.07 Bn 323.01 Bn 13.19 Bn
5 Novartis Ag 312.26 Bn 285.49 Bn -
6 Astrazeneca 285.31 Bn 259.20 Bn 13.26 Bn
7 Amgen 247.74 Bn 199.39 Bn 7.58 Bn
8 Gilead Sciences 207.12 Bn 182.22 Bn 6.73 Bn
9 Pfizer 166.13 Bn 113.48 Bn 12.56 Bn
10 Coherus Oncology 116.17 Mn -519.97 Mn 10.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 175.00 Mn
Sep 30, 2021 17.31 Mn
Jun 30, 2021 11.54 Mn
API Access

Coherus Oncology Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=CHRS&period=max&api_key=YOUR_API_KEY